Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives $16.56 Consensus PT from Brokerages

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has been given an average recommendation of “Buy” by the ten research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $16.5556.

Several research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Finally, Truist Financial assumed coverage on Inventiva in a research report on Thursday, March 19th. They issued a “buy” rating and a $13.00 target price for the company.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Creative Planning bought a new position in Inventiva in the 2nd quarter worth approximately $32,000. Virtu Financial LLC bought a new position in Inventiva in the 4th quarter worth approximately $60,000. XTX Topco Ltd bought a new position in Inventiva in the 4th quarter worth approximately $84,000. NewEdge Advisors LLC bought a new position in Inventiva in the 3rd quarter worth approximately $116,000. Finally, Cerity Partners LLC bought a new position in Inventiva in the 4th quarter worth approximately $93,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Trading Down 14.3%

NASDAQ:IVA opened at $4.09 on Friday. Inventiva has a one year low of $2.85 and a one year high of $7.98. The business’s 50-day simple moving average is $5.40 and its 200 day simple moving average is $5.40.

Inventiva (NASDAQ:IVA) last released its earnings results on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The business had revenue of $0.01 million during the quarter. Sell-side analysts forecast that Inventiva will post -0.8 earnings per share for the current year.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.